peptidesinstitute.org
WEIGHT LOSS

Semaglutide

Semaglutide (GLP-1 Receptor Agonist)

GLP-1 Peptide for Weight Loss

Buy Semaglutide
— authoritative voices whose published research informed this article

The information on this page is compiled from peer-reviewed research and is provided for educational and research purposes only. It is not medical advice, a diagnosis, or a treatment recommendation. Peptides discussed here may not be approved for human use in your jurisdiction. Always consult a qualified healthcare provider before starting, stopping, or modifying any health protocol.

Overview

What is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for the treatment of type 2 diabetes. It mimics the natural GLP-1 hormone that is released in the gut in response to eating. By activating GLP-1 receptors, semaglutide increases insulin secretion, decreases glucagon secretion, and slows gastric emptying, which leads to reduced appetite and caloric intake.

Semaglutide has gained significant attention for its effectiveness in promoting weight loss. In the STEP 1 trial, participants using once-weekly semaglutide 2.4 mg lost significantly more weight compared to placebo over 68 weeks.[1] STEP 2 extended these findings to adults with type 2 diabetes, who also experienced clinically meaningful weight reduction.[2] It is marketed under brand names such as Ozempic (for diabetes) and Wegovy (for weight management).

Beyond glycemic control and weight loss, semaglutide has demonstrated cardiovascular benefit. The SUSTAIN-6 trial showed that semaglutide reduced the rate of major adverse cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.[3] This combination of metabolic and cardiovascular effects makes it one of the most clinically validated peptides in modern endocrinology.

Research Supply

Source high-purity Semaglutide for your research

Buy Semaglutide
Protocol

Dosage Guide

Route: Subcutaneous injection, once weekly

Dosing Schedule

PeriodDose
Weeks 1-40.25 mg
Weeks 5-80.5 mg
Weeks 9-121.0 mg
Weeks 13-161.7 mg
Week 17+2.4 mg (maintenance)

Reconstitution

VIAL SIZE5 mg
WATER VOLUME2 mL
CONCENTRATION2.5 mg/mL
Each 0.1 mL (10 units on a U-100 insulin syringe) = 0.25 mg

Injection Volumes

DoseVolumeSyringe Units
0.25 mg0.1 mL10 units
0.5 mg0.2 mL20 units
1.0 mg0.4 mL40 units
1.7 mg0.68 mL68 units
2.4 mg0.96 mL96 units

Administration Tips

  • Inject subcutaneously in the abdomen, thigh, or upper arm
  • Rotate injection sites to prevent lipodystrophy
  • Inject on the same day each week at any time of day
  • Store reconstituted solution in the refrigerator and use within 28 days
Safety

Risks & Side Effects

Commonly Reported

Nausea (especially during dose escalation)VomitingDiarrheaConstipationAbdominal painHeadacheFatigueInjection site reactions

Serious Risks

Pancreatitis

Inflammation of the pancreas; discontinue use if suspected.

Gallbladder problems

Including gallstones and cholecystitis.

Kidney injury

Usually related to dehydration from gastrointestinal side effects.

Hypoglycemia

Especially when combined with other diabetes medications.

Allergic reactions

Including anaphylaxis in rare cases.

Thyroid C-cell tumors

Semaglutide carries a boxed warning for risk of thyroid C-cell tumors based on animal studies; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Related Research

Related Peptides

Expert Voices

Experts Covering Semaglutide

Dr. William A. Seeds

MD -- Regenerative Medicine Pioneer

Dr. Andrew Huberman

PhD -- Stanford Neuroscientist

Jay Campbell

Health Optimization Author and Peptide Advocate

Dr. Ian W. Hamley

Diamond Professor of Physical Chemistry -- University of Reading

Dr. Daniel J. Drucker

MD, FRCPC, FRSC -- GLP-1 Discovery Pioneer

LEGAL DISCLAIMER

The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.

Frequently Asked Questions

What is semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural GLP-1 gut hormone. It suppresses appetite, slows gastric emptying, and increases insulin secretion in a glucose-dependent manner. Marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, it is one of the most clinically validated weight-loss peptides available.
How does semaglutide work for weight loss?
Semaglutide binds GLP-1 receptors in the brain's appetite-regulating centers, reducing hunger and promoting satiety. It also slows gastric emptying, prolonging the feeling of fullness after meals. The result is a significant reduction in caloric intake. Clinical trials show average body weight reductions of approximately 15% over 68 weeks at the 2.4 mg weekly dose.
What is the difference between Ozempic and Wegovy?
Both Ozempic and Wegovy contain semaglutide, but they differ in approved indications and dosing. Ozempic (up to 2 mg) is approved for type 2 diabetes management. Wegovy (up to 2.4 mg) is FDA-approved specifically for chronic weight management in adults with obesity or overweight with a weight-related condition.
What are semaglutide side effects?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation.[1] Serious risks include pancreatitis, gallbladder problems, kidney injury from dehydration, and a boxed warning for thyroid C-cell tumors based on rodent studies. It is contraindicated in those with medullary thyroid carcinoma history.
What is the semaglutide dosage for weight loss?
The standard Wegovy titration schedule starts at 0.25 mg weekly for four weeks, escalating every four weeks through 0.5 mg, 1.0 mg, and 1.7 mg, reaching the 2.4 mg maintenance dose at week 17. This gradual escalation is designed to minimize nausea and other gastrointestinal side effects during the adjustment period.
How long does it take for semaglutide to work?
Most people experience reduced appetite within the first one to two weeks of use. Meaningful weight loss typically becomes apparent within four to eight weeks. Peak weight-loss results in clinical trials were observed at 68 weeks. The full benefit requires consistent long-term use; discontinuing semaglutide often leads to weight regain.
Semaglutide vs tirzepatide: which is better for weight loss?
Tirzepatide has shown greater average weight loss than semaglutide in clinical trials -- approximately 21% versus 15% body weight reduction.[1] Tirzepatide's dual GIP and GLP-1 agonism provides a broader metabolic effect. However, direct head-to-head trials are limited, and individual responses vary. Both are established therapies with strong clinical evidence.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. PMID 33567185
  2. Davies M, Færch L, Jeppesen OK, et al.. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021. PMID 33667417
  3. Marso SP, Bain SC, Consoli A, et al.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016. PMID 27633186

Regulatory & Official Sources